QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-fifth of one redeemable warrant |
||||
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| ☒ | Smaller reporting company | |||||
| Emerging growth company | ||||||
Page |
||||
| 1 | ||||
| 1 | ||||
| 1 | ||||
| 2 | ||||
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 15 | ||||
| 19 | ||||
| 19 | ||||
| 20 | ||||
| 20 | ||||
| 20 | ||||
| 21 | ||||
| 22 | ||||
Item 1. |
Interim Financial Statements. |
March 31, |
December 31, |
|||||||
2022 |
2021 |
|||||||
(unaudited) |
|
|||||||
| ASSETS |
||||||||
| Current assets |
||||||||
| Cash |
$ | $ | ||||||
| Prepaid expenses |
||||||||
| |
|
|
|
|||||
| Total Current Assets |
||||||||
| Marketable securities held in Trust Account |
||||||||
| |
|
|
|
|||||
| TOTAL ASSETS |
$ |
$ |
||||||
| |
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT |
||||||||
| Current liabilities |
||||||||
| Accounts payable and accrued expenses |
$ | $ | ||||||
| |
|
|
|
|||||
| Total Current Liabilities |
||||||||
| Warrant liabilities |
||||||||
| Deferred underwriting fee payable |
||||||||
| |
|
|
|
|||||
| TOTAL LIABILITIES |
||||||||
| |
|
|
|
|
|
|
|
|
| Commitments and Contingencies |
||||||||
| Class A common stock subject to possible redemption |
||||||||
| Stockholders’ Deficit |
||||||||
| Preferred stock, $ |
||||||||
| Class B common stock, $ |
||||||||
| Additional paid-in capital |
||||||||
| Accumulated deficit |
( |
) | ( |
) | ||||
| |
|
|
|
|||||
| Total Stockholders’ Deficit |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT |
$ |
$ |
||||||
| |
|
|
|
|||||
For the Three Months Ended March 31, |
For the Three Months Ended March 31, |
|||||||
2022 |
2021 |
|||||||
Operating and formation costs |
$ | $ | ||||||
Loss from operations |
( |
) |
( |
) | ||||
Other income (expenses): |
||||||||
Change in fair value of warrant liabilities |
( |
) | ||||||
Transaction costs allocated to warrant liabilities |
( |
) | ||||||
Interest earned on marketable securities held in Trust Account |
||||||||
Unrealized gain on marketable securities held in Trust Account |
||||||||
Total other income (expense), net |
( |
) | ||||||
Net income (loss) |
$ |
$ |
( |
) | ||||
Basic and diluted weighted average shares outstanding, Class A common stock |
||||||||
Basic and diluted net income (loss) per share, Class A common stock |
$ |
$ |
( |
) | ||||
Basic and diluted weighted average shares outstanding, Class B common stock |
||||||||
Basic and diluted net income (loss) per share, Class B common stock |
$ |
$ |
( |
) | ||||
Class A Common Stock |
Class B Common Stock |
Additional Paid-in |
Accumulated |
Total Stockholders’ |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Capital |
Deficit |
Deficit |
||||||||||||||||||||||
| Balance – January 1, 2022 |
$ | $ |
$ | $ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| Net incom e |
— | — | — | — | — | |||||||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance – March 31, 2022 |
$ | $ |
$ | $ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Class A Common Stock |
Class B Common Stock |
Additional Paid-in |
Accumulated |
Total Stockholders’ |
||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
Capital |
Deficit |
Equity (Deficit) |
||||||||||||||||||||||
| Balance – January 1, 2021 |
$ |
$ |
$ |
$ |
( |
) |
$ |
|||||||||||||||||||||
| Remeasurement adjustment on redeemable common stock |
— | — | — | — | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
| Sale of |
— | — | — | — | — | |||||||||||||||||||||||
| Net los s |
— | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance – March 31, 2021 |
$ | $ |
$ | $ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
For the Three Months Ended March 31, |
For the Three Months Ended March 31, |
|||||||
2022 |
2021 |
|||||||
| Cash Flows from Operating Activities: |
||||||||
| Net income (loss) |
$ | $ | ( |
) | ||||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: |
||||||||
| Change in fair value of warrant liabilities |
( |
) | ||||||
| Transaction costs allocated to warrant liabilities |
||||||||
| Interest earned on marketable securities held in Trust Account |
( |
) | ( |
) | ||||
| Unrealized gain on marketable securities held in Trust Account |
( |
) | ( |
) | ||||
| Changes in operating assets and liabilities: |
||||||||
| Prepaid expenses |
( |
) | ||||||
| Accounts payable and accrued expenses |
||||||||
| |
|
|
|
|||||
| Net cash used in operating activities |
( |
) |
( |
) | ||||
| |
|
|
|
|||||
| Cash Flows from Investing Activities: |
||||||||
| Investment of cash in Trust Account |
( |
) | ||||||
| |
|
|
|
|||||
| Net cash used in investing activities |
( |
) | ||||||
| |
|
|
|
|||||
| Cash Flows from Financing Activities: |
||||||||
| Proceeds from sale of Units, net of underwriting discounts paid |
||||||||
| Proceeds from sale of Private Placement Warrants |
||||||||
| Proceeds from promissory notes – related party |
||||||||
| Repayment of promissory notes – related party |
( |
) | ||||||
| Payment of offering costs |
( |
) | ||||||
| |
|
|
|
|||||
| Net cash provided by in financing activities |
||||||||
| |
|
|
|
|||||
| Net Change in Cash |
( |
) |
||||||
| Cash – Beginning |
$ | |||||||
| |
|
|
|
|||||
| Cash – Ending |
$ |
$ |
||||||
| |
|
|
|
|||||
| Non-cash investing and financing activities: |
||||||||
| Offering costs included in accrued offering costs |
$ | $ | ||||||
| |
|
|
|
|||||
| Remeasurement adjustment on redeemable common stock |
$ | $ | ||||||
| |
|
|
|
|||||
| Deferred underwriting fee payable |
$ | $ | ||||||
| |
|
|
|
|||||
For the Three Months Ended March 31, |
For the Three Months Ended March 31, |
|||||||||||||||
2022 |
2021 |
|||||||||||||||
Class A |
Class B |
Class A |
Class B |
|||||||||||||
Basic and diluted net income (loss) per common stock |
||||||||||||||||
Numerator: |
||||||||||||||||
Allocation of net income (loss), as adjusted |
$ | $ | $ | ( |
) | $ | ( |
) | ||||||||
Denominator: |
||||||||||||||||
Basic and diluted weighted average shares outstanding |
||||||||||||||||
Basic and diluted net income (loss) per common stock |
$ | $ | $ | ( |
) | $ | ( |
) | ||||||||
| Level 1: | Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. | |
| Level 2: | Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. | |
| Level 3: | Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. | |
Level |
December 31, 2021 |
March 31, 2022 |
||||||||||
Assets: |
||||||||||||
Marketable securities held in Trust Account |
1 | $ | $ | |||||||||
Liabilities: |
||||||||||||
Warrant Liability – Private Placement Warrants |
1 | |||||||||||
Warrant Liability – Public Warrants |
2 | |||||||||||
Private Placement |
Public |
Warrant Liabilities |
||||||||||
Fair value as of December 31, 2021 |
$ | $ | $ | |||||||||
Change in valuation inputs or other assumptions |
( |
) | ( |
) | ( |
) | ||||||
Fair value as of March 31, 2022 |
$ | $ | $ | |||||||||
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
Item 4. |
Controls and Procedures |
| Item 1A. | Risk Factors |
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds. |
Item 6. |
Exhibits |
No. |
Description of Exhibit | |
| 31.1* | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 31.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
| 32.1** | Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
| 101.INS* | Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Online XBRL Document | |
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB* | Inline XBRL Taxonomy Extension Labels Linkbase Document | |
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104* | The cover page from the Company’s Quarterly report on Form 10-Q for the quarter ended March 31, 2022 has been formatted in Inline XBRL and is included in Exhibits 101. | |
| * | Filed herewith. |
| ** | Furnished. |
PIVOTAL INVESTMENT CORPORATION III | ||||||
| Date: May 16, 2022 | By: | /s/ Kevin Griffin | ||||
| Name: | Kevin Griffin | |||||
| Title: | Chief Executive Officer and | |||||
| (Principal Executive Officer Officer) | ||||||
| Date: May 16, 2022 | By: | /s/ Jim Brady | ||||
| Name: | Jim Brady | |||||
| Title: | Chief Financial Officer | |||||
| (Principal Financial and Accounting Officer) | ||||||